Antisense- and RNA interference-based therapeutic strategies in allergy

Journal of Cellular and Molecular Medicine

Volumn 9, Issue 4, 2005, Pages 840-853

  Popescu, Florin Dan ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Allergy; Antisense oligonucleotides; DNAzymes; Ribozymes; RNA interference; Small interfering RNAs

Indexed keywords

EID: 30944443047     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2005.tb00383.x     Document Type: Review

References (77)

1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113: 832-6.
2. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol. 2003; 21: 1457-65.
3. Ball HA, van Scott MR, Robinson CB. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin Rev Allergy Immunol 2004; 27: 207-17.
4. Wild LG, Lehrer SB. Immunotherapy for food allergy. Curr Allergy Rep. 2001; 1: 48-53.
5. Popescu FD. New asthma drugs acting on gene expression. J Cell Mol Med. 2003; 7: 475-86.
6. Howard TD, Meyers DA, Bleecker ER. Mapping susceptibility genes for allergic diseases. Chest 2003; 123: 363-8.
7. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, Pandit S, McKenny J, Braunschweiger K, Walsh A, Liu Z, Hayward B, Folz C, Manning SP, Bawa A, Saracino L, Thackston M, Benchekroun Y, Capparell N, Wang M, Adair R, Feng Y, Dubois J, Fitzgerald MG, Huang H, Gibson R, Allen KM, Pedan A, Danzig MR, Umland SP, Egan RW, Cuss FM, Rorke S, Clough JB, Holloway JW, Holgate ST, Keith TP. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418: 426-30.
8. Holgate ST, Davies DE, Rorke S, Cakebread J, Murphy G, Powell RM, Holloway JW. Identification and possible functions of ADAM33 as an asthma susceptibility gene. Clin Exp Allergy Rev. 2004; 4: 49-55.
9. Ball HA, Sandrasagra A, Tang L, van Scott M, Wild J, Nyce JW. Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am J Pharmacogenomics. 2003; 3: 97-106.
10. Popescu FD. Pharmacological modulation of gene expression in asthma (review in Japanese and English). International Review of Asthma (Japan). 2005; 7: 74-90.
11. Grzela K, Lazarczyk M, Dziunycz P, Milewski L, Niderla J, Grzela T. Molecular therapy versus standard treatment in allergy (review). Int J Mol Med. 2004; 14: 3-22.
12. Brysch W. The design of appropriate control experiments to ensure specificity in antisense oligonucleotide function. In: Leslie RA, Hunter J, Robertson HA, editors. Antisense technology in the central nervous system. USA Oxford University Press, 2000, p. 22-41.
13. Isenberg-Feig H, Justice JP, Keane-Myers A. Animal models of allergic asthma. Curr Allergy Asthma Reports. 2003; 3: 70-8.
14. Coffman RL, Hessel EM. Nonhuman primate models of asthma. J Exp Med. 2005; 201: 1875-9.
15. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem. 2003; 270: 1628-44.
16. Tanaka M, Nyce J. Respirable antisense oligonucleotides: a new drug class for respiratory disease. Respir Res. 2001; 2: 5-9.
17. Ali S, Leonard SA, Kukoly CA, Metzger WJ, Wooles WR, McGinty JF, Tanaka M, Sandrasagra A, Nyce JW. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am J Respir Crit Care Med. 2001; 163: 989-93.
18. Sandrasagra A, Leonard SA, Tang L, Teng K, Ball HA, Mannion JC, Nyce JW. Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 2002; 12: 177-81.
19. Paterson D. Asthma: new drug targets and innovative therapeutics (London). IDrugs 2001; 4: 646-9.
20. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H, Neurath MF. Treatment of allergic inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med. 2001; 193: 1247-60.
21. Stenton GR, Kim MK, Nohara O, Khen CF, Hirji N, Wills FL, Gilchrist M, Hwang PH, Park JG, Finlay W, Jones RL, Befus AD, Schreiber AD. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol. 2000; 164: 3790-7.
22. Stenton GR, Ulanova M, Dery RE, Merani S, Kim MK, Gilchrist M, Puttagunta L, Musat-Marcu S, James D, Schreiber AD, Befus AD. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol. 2002; 169: 1028-36.
23. Bochner BS. Adhesion molecules as therapeutic targets. Immunol Allergy Clin N Am. 2004; 24: 615-30.
24. Nyce J. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease. Curr Opin Allergy Clin Immunol. 2002; 2: 533-6.
25. Kim HM, Kim KS, Lee EH. Specific inhibition of immunoglobulin E-mediated allergic reaction using antisense Fc-ε RI-α oligodeoxynucleotides. Immunology 1998; 93: 589-94.
26. Lach-Trifilieff E, McKay RA, Monia BP, Karras JG, Walker C. In vitro and in vivo inhibition of interleukin IL-5-mediated eosinopoiesis by murine IL-5Rα antisense oligonucleotides. Am J Respir Cell Mol Biol. 2001; 24: 116-22.
27. Allam M, Renzi PM. Inhibition of GM-CSF/IL-3/IL-5 signaling by antisense oligodeoxynucleotides targeting the common beta chain of their receptors. Antisense Nucleic Acid Drug Dev. 2001; 11: 289-300.
28. Allakhverdi Z, Allam M, Renzi PM. Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common β chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med. 2002; 165: 1015-21.
29. Lofthouse SA, Crosby JR, Tung D, Guha M, Kowalski D, Luther D, Arberg CC, Lin D, Osgood T, McKay K, Gaarde B, Tachas G, Wraight CJ, Monia BP, Karras JG, Gregory SA. Aerosol delivery of VLA-4 specific antisense oligonucleotides inhibit airway inflammation and hyperresponsiveness in mice. Respirology 2005; 10: A11.
30. Hanai K, Kurokawa T, Minakuchi Y, Maeda M, Nagahara S, Miyata T, Ochiya T, Sano A. Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease. Hum Gene Ther. 2004; 15: 263-72.
31. Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, Fujisawa Y, Nishimura O, Fujino M. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci USA. 2001; 98: 5175-80.
32. Hikida M, Haruna K, Ohmori H. Suppression of interleukin 4 production from type 2 helper T cell clone by antisense oligodeoxynucleotide. Immunol Lett. 1992; 34: 297-302.
33. Benbernou N, Matsiota-Bernard P, Guenounou M. Antisense oligonucleotides to interleukin-4 regulate IgE and IgG2a production by spleen cells from Nippostrongylus brasiliensis-infected rats. Eur J Immunol. 1993; 23: 659-63.
34. 2 clone is refractory to suppression by IL4-depletion. Int Arch Allergy Immunol. 1993; 102: 152-9.
35. Molet S, Ramos-Barbon D, Martin JG, Hamid Q. Adoptively transferred late allergic response is inhibited by IL-4, but not IL-5, antisense oligonucleotide. J Allergy Clin Immunol. 1999; 104: 1188.
36. Fiset PO, Soussi-Gounni A, Christodoulopoulos P, Tulic M, Sobol SE, Frenkiel S, Lavigne F, Lamkhioued B, Hamid Q. Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4. J Allergy Clin Immunol. 2003; 111: 580-6.
37. Mousavi T, Mazer B, Tebianian M. Inhibition of IL-13 by antisense oligonucleotide changes immunoglobulin isotype profile in cultured B-lymphocytes. Iran Biomed J. 2004; 8: 185-91.
38. Finotto S, Buerke M, Lingnau K, Schmitt E, Galle PR, Neurath MF. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol. 2001; 107: 279-86.
39. Kim HM, Lee Y-M. Role of TGF-β1 on the IgE-dependent anaphylaxis reaction. J Immunol. 1999; 126: 4960-5.
40. Karras JG, McGraw K, McKay RA, Cooper SR, Lerner D, Lu T, Walker C, Dean NM, Monia BP. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol. 2000; 164: 5409-15.
41. Crosby JR, Tung D, Guha M, Luther D, Kowalski D, Osgood T, Gaarde B, Monia B, Karras J, Gregory SA. Inhaled TNF-α antisense oligonucleotide inhibits lung inflammation and airway hyper-responsiveness in a mouse model of chronic asthma (poster 311). ATS 2005 San Diego, Abstract Page: A905.
42. Pazdrak K, Olszewska-Pazdrak B, Stafford S, Garofalo RP, Alam R. Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med. 1998; 188: 421-9.
43. Stafford S, Lowell C, Sur S, Alam R. Lyn tyrosine kinase is important for IL-5-stimulated eosinophil differentiation. J Immunol. 2002; 168: 1978-83.
44. Ulanova M, Puttagunta L, Kim MK, Schreiber AD, Befus AD. Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders. Curr Opin Investig Drugs. 2003; 4: 552-5.
45. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JQ Wong WS. Inhaled p38 α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med. 2005; 171: 571-8.
46. Choi IW, Kim DK, Ko HM, Lee HK. Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-κB inhibits established asthmatic reaction in mice. Int Immunopharmacol. 2004; 4: 1817-28.
47. Hill S, Herlaar E, Le Cardinal A, Van Heeke G, Nicklin P. Homologous human and murine antisense oligonucleotides targeting STAT6. Am J Respir Cell Mol Biol. 1999; 21: 728-37.
48. Peng Q, Matsuda T, Hirst SJ. Signaling pathways regulating interleukin-13-stimulated chemokine release from airway smooth muscle. Am J Respir Crit Care Med. 2004; 169: 596-603.
49. Bagheri S, Kashani-Sabet M. Ribozymes in the age of molecular therapeutics. Curr Mol Med. 2004; 4: 489-506.
50. Cairns MJ, Sun LQ. Target-site selection for the 10-23 DNAzyme. Methods Mol Biol. 2004; 252: 267-77.
51. Jen KY, Gewirtz AM. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells 2000; 18: 307-19.
52. Freelove AC, Zheng R. The power of ribozyme technologies: the logical way ahead for molecular medicine and gene therapy? Curr Opin Mol Ther. 2002; 4: 419-22.
53. Sandberg JA, Lee PA, Usman LN. Ribozyme therapy. In: Hansel TT, Barnes PJ, editors. New drugs for asthma, allergy and COPD. Basel: Karger, Prog Respir Res, 2001. vol 31, p. 370-3.
54. Dreyfus DH, Matczuk A, Fuleihan R. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor α mRNA. Int Immunopharmacol. 2004; 4: 1015-27.
55. Zhang H, Altman S. Inhibition of the expression of the human RNase P protein subunits Rpp21, Rpp25, Rpp29 by external guide sequences (EGSs) and siRNA. J Mol Biol. 2004; 342: 1077-83.
56. Wadhwa R, Kaul SC, Miyagishi M, Taira K. Know-how of RNA interference and its applications in research and therapy. Mutat Res. 2004; 567: 71-84.
57. Bagasra O, Prilliman KR. RNA interference: the molecular immune system. J Mol Histol. 2004; 35: 545-53.
58. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 2002; 527: 274-8.
59. 2 in human and rat mast cell lines. J Biol Chem. 2003; 278: 4725-9.
60. Platz J, Pinkenburg O, Beisswenger C, Puchner A, Damm T, Bals R. Application of small interfering RNA (siRNA) for modulation of airway epithelial gene expression. Oligonucleotides 2005; 15: 132-8.
61. Guo J, Fu YC, Becerra CR. Dissecting role of regulatory factors in NF-κB pathway with siRNA. Acta Pharmacol Sin. 2005; 26: 780-8.
62. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol. 2003; 327: 761-6.
63. Scherr M, Battmer K, Dallmann I, Ganser A, Eder M. Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. Oligonucleotides 2003; 13: 353-63.
64. Agrawal S, Kandimalla ER. Role of Toll-like receptors in antisense and siRNA. Nat Biotechnol. 2004; 22: 1533-7.
65. Vollmer J. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin Biol Ther. 2005; 5: 673-82.
66. Senn JJ, Bur el S, Henry SP. Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther. 2005; 314: 972-9.
67. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol. 2004; 22: 1579-82.
68. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004; 431: 211-7.
69. Bi F, Liu N, Fan D. Small interfering RNA: a new tool for gene therapy. Curr Gene Ther. 2003; 3: 411-7.
70. Kalota A, Shetzline SE, Gewirtz AM. Progress in the development of nucleic acid therapeutics for cancer. Cancer Biol Ther. 2004; 3: 4-12.
71. Krause JR, Shahidi-Asl M. Molecular pathology in the diagnosis and treatment of non-Hodgkin's lymphomas. J Cell Mol Med. 2003 Oct-Dec;7(4):494-512.
72. Haulica I. From molecular genetics to functional genomics and physiome. J Cell Mol Med. 2002 Oct-Dec;6(4):648-52.
73. Smythe GM, Hodgetts SI, Grounds MD. Problems and solutions in myoblast transfer therapy. J Cell Mol Med. 2001 Jan-Mar;5(1):33-47.
74. Kemp PJ, Peers C, Lewis A, Miller P. Regulation of recombinant human brain tandem P domain K+ channels by hypoxia: a role for O2 in the control of neuronal excitability? J Cell Mol Med. 2004 Jan-Mar;8(1):38-44.
75. Perkins D. Targeting apoptosis in neurological disease using the herpes simplex virus. J Cell Mol Med. 2002 Jul-Sep;6(3):341-56.
76. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005; 9: 360-72.
77. Scanlon KJ. Anti-genes: siRNA, ribozymes and antisense. Curr Pharm Biotechnol. 2004; 5: 415-20.